• Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.

  NCT04795661

  Active, not recruitingInterventionalPhase 2Updated Jan 7, 2026
• Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

  NCT02563002

  CompletedInterventionalPhase 3Updated Oct 3, 2024
• Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer

  NCT07409844

  Not yet recruitingInterventionalPhase 2Updated Feb 20, 2026
• Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers

  NCT05131919

  Active, not recruitingInterventionalPhase 2Updated Dec 9, 2025
• Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)

  NCT02460198

  CompletedInterventionalPhase 2Updated Jul 27, 2023
• Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer

  NCT06428487

  CompletedInterventionalPhase 2Updated Apr 27, 2026

ClinicalTrials.gov ID

NCT06646445

Lead Sponsor

GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

60Estimated

Last Update Posted

Jun 13, 2025Actual

Start Date

Sep 2025Estimated

Primary Completion Date

Dec 2027Estimated

Completion Date

Dec 2029Estimated

Official Title

Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for Patients With Mismatch Repair-deficient or Microsatellite Instability-high (dMMR/MSI-H) Localized Colon Cancer: a Randomized GERCOR G-109 PRODIGE 84 PREMICES Phase II Trial

Brief Summary

The goal of this investigational, multicenter, open-label randomized, two-stage phase II study is to evaluate neoadjuvant pembrolizumab with a watch-and-wait approach in patients with localized deficient mismatch repair / high microsatellite instability (dMMR/MSI-H) colorectal cancer (CRC). The PREMICES trial is based on the hypothesis that non-operative management is effective for dMMR/MSI-H localized CRC when treated with neoadjuvant pembrolizumab.

Eligible patients will be randomized in a 1:1 ratio to receive either pembrolizumab with a watch-and-wait approach (experimental arm A) or the standard strategy of surgical resection ± adjuvant chemotherapy (arm B).

Detailed Description

dMMR/MSI-H is a key biomarker for predicting the success of immune checkpoint inhibitors in colorectal cancer (CRC). Pembrolizumab has shown improved outcomes for patients with metastatic CRC, becoming the new standard of care. Neoadjuvant immunotherapy has demonstrated high rates of complete pathological responses in both metastatic and localized CRC, with promising results in non-surgical approaches. Studies support using a "watch-and-wait" strategy after immunotherapy, potentially avoiding surgery. These findings are reshaping treatment strategies for dMMR/MSI-H CRC, particularly regarding organ preservation and non-operative management.

The PREMICES study evaluates the efficacy of neoadjuvant pembrolizumab combined with a watch-and-wait approach for treating localized dMMR/MSI-H CRC. It investigates non-operative management as a potential strategy for achieving a complete clinical response in dMMR/MSI-H localized CRC without the need for surgery.

• Colon Cancer

• Pembrolizumab Injection [Keytruda]
• Watch-and-wait approach
• Surgery
• Adjuvant chemotherapy

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Signed and dated informed consent (IC),

2. Aged ≥18 years,

3. An Eastern Cooperative Oncology Group Performance status (ECOG PS) of 0 or 1,

4. Newly diagnosed, histologically confirmed colonic or upper third rectal adenocarcinoma, NB: material must be available from biopsy done during colonoscopy.

5. Radiological tumor assessment at screening performed within 21 days before inclusion according to RECIST v1.1 by chest, abdomen, and pelvis (TAP- CT) showing resectable localized disease (cT0-4 cN0-2 cM0) and no metastatic disease,

6. dMMR and/or MSI-high (MSI-H) tumor status as follows:

   • loss of expression of ≥1 MMR protein (MLH1, MSH2, MSH6, or PMS2) or a dimeric couple (MLH1 and PMS2 or MSH2 and MSH6) on immunohistochemistry (IHC; using hMLH1, hMSH2, hMSH6, hPMS2 antibodies),
   • And/or ≥ 3 instable markers by the pentaplex by polymerase chain reaction (PCR) (BAT-25, BAT-26, NR-21, NR-24, and NR-27),

   NB:

   • In case of two instable markers by PCR, it is required to present confirmation of the dMMR status by IHC or comparison of PCR test with matched normal tissue.
   • In case of loss of expression of only one MMR protein by IHC or any other IHC pattern, it is required to confirm MSI status using pentaplex PCR; Agreement of Sponsor on a dMMR/MSI status is mandatory to include the patient (the patient's file [an anonymized mail] must be send to Sponsor before inclusion). Approval/refusal email for inclusion of the patient will be sent by Sponsor within 24 hours of receipt of the Investigator email. In case of discrepancy between IHC and PCR, the final decision about the dMMR/MSI status will be taken by Sponsor or coordinating investigator,

7. Adequate hematological status, renal, and liver function obtained within 14 days prior to randomization of study treatment:

   1. absolute neutrophil count (ANC) ≥1.5 x 10^9/L; platelets ≥100 x 10^9/L; hemoglobin ≥9 g/dL,
   2. serum creatinine level <150 µM or clearance >50 ml/min (Modification of the Diet in Renal Disease [MDRD] or Cockcroft and Gault),
   3. serum bilirubin ≤1.5 × upper limit of normal (ULN), alkaline phosphatase <5 x ULN, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 2.5 x ULN,

8. International normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤1.5 × ULN, except for the patient on anticoagulant therapy who must have PT-INR-aPTT within therapeutic range is deemed appropriate by the Investigator,

9. Has no contraindications to administration of oxaliplatin, capecitabine, or 5-fluorouracil, according to their respective summaries of product characteristics (SmPCs),

10. Is able to undergo surgery and receive adjuvant treatment (chemotherapy) as part of standard care,

11. A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

    1. Is a woman of non-childbearing potential as defined: i/ ≥45 years of age and has not had menses for >1 year, ii/ amenorrhea for <2 years without a hysterectomy and oophorectomy and have a high follicle stimulating hormone (FSH) value in the postmenopausal range upon pre-study (screening) evaluation, iii/ post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, MRI, or CT scan,
    2. Negative pregnancy blood test within 72 hours before the first dose of pembrolizumab, AND
    3. If woman of childbearing potential (WOCBP), female patient must be willing to use a highly effective form of contraception (Appendix 24.9) from screening throughout the study treatment and 4 months after the last dose of pembrolizumab,

12. Male patient is eligible to participate if he agrees to the following during the study treatment and for 4 months after the last dose of pembrolizumab:

    1. Refrain from donating sperm,

    2. Must use contraception/barrier as follows:

       • Agree to use a male condom when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant.
       • Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person,

13. Primary tumor tissue samples (archival or fresh biopsy specimen) acquired during coloscopy together with images availability (mandatory), NB: The patient's agreement will be specifically requested for endoscopic images in the patient information note and informed consent for their use as clinical data that may be analyzed and presented in publications. These data will be used in the same manner as other personal data. The confidentiality of these data will be maintained,

14. Patient willing and able to comply with scheduled visits, treatment schedule, laboratory tests, tumor biopsies, and other requirements of the study,

15. Registeration in the National Health Care System (PUMa - Protection Universelle Maladie included).

Exclusion Criteria:

1. Tumor that is not readily resectable,

2. Bifocal colorectal adenocarcinoma,

3. Locally advanced middle or low rectal cancer (<10 cm from the anal verge on MRI, sagittal slide) staged as cT3/T4 and/or N+ and/or with predictive circumferential margin >2 mm on pretreatment MRI, NB: for rectal cancers, the margin of the tumor relative to the anal margin should be indicated on the endoscopy report,

4. Major surgical procedure within 4 weeks prior to the first dose of study treatment,

5. Pre-existing hemostatic disorder or medical condition requiring chronic anticoagulation that cannot be interrupted for the purpose of study specified tumor resection or endoscopic biopsies,

6. Metastases (stage IV disease),

7. Has history of uncontrolled or symptomatic cardiac disease,

8. Prior treatment with an anti-PD(L)1, anti-LAG-3, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, including prior therapy with anti-tumor vaccines or other immuno-stimulatory antitumor agents,

9. Prior malignancy active within the previous 3 years apart from: i/ locally curable cancers that have been apparently cured (e.g., squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast); ii/ Lynch syndrome-related non-CRC in complete remission for > 1 year,

10. Patient is human immunodeficiency virus (HIV)-positive with CD4+ cell count <600 cell/ml or detectable viral load,

11. Has complete or partial dihydropyrimidine dehydrogenase deficiency (uracilemia ≥16 ng/ml), In particular, the uracilemia level must be determined before patient inclusion. Patients with altered uracilemia will be excluded.

12. Patient has active hepatitis B virus (HBV, defined as having a positive hepatitis B surface antigen [HBsAg] test) or hepatitis C virus (HCV) prior to inclusion, NB: Patients with past HBV infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen antibody test) are eligible. NB: Patients positive for HCV antibody are eligible only if PCR testing is negative for HCV RNA.

13. Impossibility of submitting to the medical follow-up of the study for geographical, social, or psychiatric illness.

14. Patient under a legal protection regime (guardianship, curatorship, judicial safeguard) or administrative decision or incapable of giving his/her consent,

    Non-eligible to immunotherapy:

15. Any history of autoimmune disease including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis, NB: History of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.

    NB: Controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.

16. Prior (non-infectious) pneumonitis requiring systemic corticosteroid therapy or has currently pneumonitis,

17. Any live, attenuated vaccine within 30 days prior to the first dose of study treatment or such administration is anticipated during the study,

18. Prior allogeneic bone marrow transplantation or prior solid organ transplantation,

19. Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 14 days (2 weeks) prior to the first dose of trial treatment or is required to receive systemic immunosuppressive medications during the study. Inhaled or topical steroids and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

20. Ongoing anti-cancer treatment for another cancer (to be discussed with the coordinator in case of hormone therapy in patients with prostate and breast cancer),

21. Known hypersensitivity to any of the excipients of pembrolizumab, NB: L-histidine, L-Histidine Hydrochloride monohydrate, sucrose, polysorbate-80 (E433).

NB: L-histidine, L-Histidine Hydrochloride monohydrate, sucrose, polysorbate-80 (E433).

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER

Collaborators

Fondation ARCADOTHER

a3vienot@chu-besancon.fr0370632403

benoist.chibaudel@ihfb.org0147595965

aurelien.dupre@lyon.unicancer.fr0478782933

odubreuil@hopital-dcss.org0144742839

romain.cohen@aphp.fr0149282336

raphael.colle@imm.fr0156616241

eric.terrebonne@chu-bordeaux.fr0557656439

david.tougeron@chu-poitiers.fr0549444886

guimbaud.r@chu-toulouse.fr0561322142